MARCHF1

Across TCGA pan-cancer cohorts, MARCHF1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MARCHF1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MARCHF1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MARCHF1 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, HNSC, and KIRP are the cancer types where MARCHF1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MARCHF1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+1.304	<.001	12	view →
HNSC	Female	III,IV	+0.948	<.001	11	view →
KIRP	All	All	+0.713	<.001	9	view →
LUSC	All	II,III,IV	−0.695	<.001	8	view →
STAD	All	II,III,IV	+0.774	<.001	6	view →
BRCA	All	II,III,IV	+0.558	<.001	6	view →
KICH	Female	All	+1.471	<.001	5	view →
CHOL	All	All	+1.131	<.001	5	view →
THCA	All	IV	+0.847	.002	3	view →
COAD	All	All	−0.312	.011	3	view →
UCEC	All	All	−0.343	.009	2	view →
ESCA	All	All	+0.683	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MARCHF1–KIRC

Open the KIRC breakdown →